RAPTIVA®

(Efalizumab)

Documentation

Patented
Approved 2003
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: CD11a(LFA-1)
Indication Category: Autoimmunity

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA